| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 Laboratory for Brain Tumour Biology, Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany
2 Department of Neurology, Klinikum Nord Ochsenzoll, Hamburg, Germany
3 Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
4 Department of Maxillofacial Surgery, University Hospital Hamburg-Eppendorf, Germany
Correspondence to:
Dr L Kluwe, Department of Maxillofacial Surgery, University Hospital Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany;
kluwe{at}uke.uni-hamburg.de]
Neurofibromatosis 2 (NF2) is a severe autosomal dominant disorder that predisposes to multiple tumours of the nervous system. About half of all patients are founders with clinically unaffected parents. The purpose of the present study was to examine the extent to which mosaicism is present in NF2 founders. A total of 233 NF2 founders with bilateral vestibular schwannomas (BVS) were screened by exon scanning. NF2 mutations were detected in the blood samples of 122 patients (52%). In 10 of the 122 cases, the ratio of mutant to normal alleles was obviously less than 1, suggesting mosaicism. Tumour specimens were available from 35 of the 111 subjects in whom no mutation could be detected in blood specimens. Mutational analysis by exon scanning detected typical NF2 mutations in 21 of the 35 tumours. In nine subjects, the alterations found in tumours could be confirmed to be the constitutional mutation based on finding of identical mutations in pathologically and/or anatomically distinct second tumours. In six other subjects with only a single tumour available, allelic loss of the NF2 gene was found in addition to the mutation in each tumour, suggesting that either the mutation or the deletion of the NF2 gene is probably the constitutional genetic alteration. Our results suggest that failure to find constitutional mutations in blood specimen from these 15 patients was not because of the limitation of the applied screening technique, but the lack of the mutations in their leucocytes, best explained by mosaicism. Extrapolating the rate (15/35 = 43%) of mosaicism in these 35 cases to the 111 NF2 founders with no constitutional NF2 mutations found in their blood, we inferred 48 mosaic subjects (111 x 0.429). Adding the 10 mosaic cases detected directly in blood specimens, we estimate the rate of mosaicism to be 24.8% (58/233) in our cohort of 233 NF2 founders with bilateral vestibular schwannomas.
Keywords: neurofibromatosis 2 (NF2); mosaicism; mutation; loss of heterozygosity (LOH)
This article has been cited by other articles:
|
|
 |
|
  M. Feucht, L. Kluwe, V.-F. Mautner, and G. Richard Correlation of Nonsense and Frameshift Mutations With Severity of Retinal Abnormalities in Neurofibromatosis 2 Arch Ophthalmol, October 1, 2008; 126(10): 1376 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Kehrer-Sawatzki and D N Cooper Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes? J. Med. Genet., October 1, 2008; 45(10): 622 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Hanemann Magic but treatable? Tumours due to loss of Merlin Brain, March 1, 2008; 131(3): 606 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saito, R. Nishikomori, N. Kambe, A. Fujisawa, H. Tanizaki, K. Takeichi, T. Imagawa, T. Iehara, H. Takada, T. Matsubayashi, et al. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients Blood, February 15, 2008; 111(4): 2132 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D G. R Evans, R T Ramsden, A Shenton, C Gokhale, N L Bowers, S M Huson, G Pichert, and A Wallace Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification J. Med. Genet., July 1, 2007; 44(7): 424 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Woodward, K. Wall, J. Forsyth, F. Macdonald, and E. R. Maher VHL mutation analysis in patients with isolated central nervous system haemangioblastoma Brain, March 1, 2007; 130(3): 836 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J Murray, T A T Hughes, J W Neal, E Howard, D G R Evans, and P S Harper A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2? J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 269 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M E Baser, L Kuramoto, R Woods, H Joe, J M Friedman, A J Wallace, R T Ramsden, S Olschwang, E Bijlsma, M Kalamarides, et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2 J. Med. Genet., July 1, 2005; 42(7): 540 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Tsilchorozidou, F H Menko, F Lalloo, A Kidd, R De Silva, H Thomas, P Smith, A Malcolmson, J Dore, K Madan, et al. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2 J. Med. Genet., July 1, 2004; 41(7): 529 - 534. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Nunes and M. MacCollin Neurofibromatosis 2 in the Pediatric Population J Child Neurol, October 1, 2003; 18(10): 718 - 724. [Abstract] [PDF]
|
|
|
|
|
|
M E Baser, L Kuramoto, H Joe, J M Friedman, A J Wallace, R T Ramsden, and D G R Evans Genotype-phenotype correlations for cataracts in neurofibromatosis 2 J. Med. Genet., October 1, 2003; 40(10): 758 - 760. [Full Text] [PDF]
|
|
|
|
|
|
A Moyhuddin, M E Baser, C Watson, S Purcell, R T Ramsden, A Heiberg, A J Wallace, and D G R Evans Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring J. Med. Genet., June 1, 2003; 40(6): 459 - 463. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
